Medical Health & Life Science Research News

Parkinson’s disease therapeutics market has a positive long-term growth outlook 2024 according to new research report

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions

- Advertising -

Parkinson's disease (PD) is a chronic and progressive neurological disorder where the symptoms continue and worsen with time. The primary symptoms include tremor, slow movements (bradykinesia), rigidity (stiffness), and balance difficulties (postural instability).

The disease has no cure currently, but the therapies available minimize the effects of its signs and symptoms. The treatment options of the disease include neurological medications, surgeries, and neurostimulation devices.

- Advertising -

Globally, the number of patients suffering from the disease is expected to reach two million by 2030, with countries in Europe such as Germany, France, and the U.K. accounting for a majority of the number.

The discovery of dopamine plays a key pathological role in Parkinson’s disease while subsequent introduction of therapeutics such as levodopa is a major milestone revolutionizing the Parkinson’s disease therapeutics market. Administration of levodopa in combination with carbidopa is a standard therapeutic treatment of Parkinson’s disease.

Comtess/Comtan, Cycloset, Rytary, and Stalevo are commercially available therapeutics. 

Browse Report for more Details: www.transparencymarketresearch.com…utics-market.html

Growing disability adjusted life years is driving the growth of the market. According to the World Health Organization, the number of people with disability-adjusted life year due to Parkinson’s disease was 1.7 million globally in 2015.

As per the European Parkinson’s Disease Association, the disease treatment cost in Europe was estimated at US$ 12.6 Mn in 2005 and is expected to double by 2030. Rising prevalence of the disease and increasing demand for new drug therapies are the key drivers of the market.

About 6.3 million people suffer from Parkinson’s disease according to the European Brain Council. 

The global Parkinson’s disease therapeutics market has been segmented based on therapeutic class, distribution channel, and region. 

In terms of therapeutic class, the market is categorized as:

  • Dopamine precursors
  • Phenobarbital
  • Primidone
  • Catechol-O-methyl transferase (COMT) inhibitors
  • Entacapone
  • Tolcapone
  • Dopamine agonists (non-ergoline)
  • Pramipexole
  • Ropinirole
  • Others (apomorphine and rotigotine)
  • Monoamine oxidase B inhibitors (MAO-B inhibitors)
  • Selegiline
  • Rasagiline
  • Others (amantadine and anticholinergic) 

Based on distribution channel, the Parkinson’s disease therapeutics market has been segmented into:

  • Hospital pharmacies
  • Online pharmacies
  • Retail pharmacies
  • Drug stores 

Based on region, the Parkinson’s disease therapeutics market has been segmented into:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa 

Availability of alternative options for the Parkinson’s disease management acts as a major restraining factor for the market growth. There is increasing level of sophistication and technological advances in neurology devices.

The increase in demand for home health care devices has led to introduction of implantable neurostimulation devices for the treatment of the disease. Health care professionals are showing favorable inclination toward advanced technologies that will offer superior quality treatment compared to the conventional therapeutics and devices.

New devices such as ultrasonic aspirators and stereotactic systems are gaining market acceptance among medical professionals. Hence, competition in the market from other improved Parkinson’s disease management methods can also hamper the growth of the market.

Research and development by pharmaceutical companies and research organizations for developing combination therapies to prolong the effect of dopaminergic drugs and to slow down the prognosis of Parkinson’s disease are major factors driving the market growth for Parkinson’s disease therapeutics.

 Report: www.transparencymarketresearch.com…&rep_id=26975

Key players operating in the market include AbbVie, Acorda Therapeutics, Inc., Biogen, Inc., Merck & Co., Novartis AG, Pfizer Inc., UCB, F-Hoffmann-La Roche Ltd, Inc., GlaxoSmithKline, and AstraZeneca plc.

 

News From

Transparency Market Research - In-depth AnalysisTransparency Market Research
Category: Market Research Publishers and RetailersCompany profile: TMR provides a range of marketing and business research solutions designed for your specific needs. From off-the-shelf syndicated business And market research to made-to-order custom research, we serve our clients to fulfill their immediate as well as ongoing research requirements.      We specialize in the following areas:   Syndicated Research Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemical, energy, food & beverage ...